Clinical Trials on Plasma Cell Neoplasm in China

Total 16287 results

Institute of Hematology & Blood Diseases Hospital

Recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

Plasma Cell Leukemia

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

Plasma Cell Leukemia

China
Shanghai Changzheng Hospital
CARsgen Therapeutics Co., Ltd.

Recruiting

Study of CT071 Injection in RRMM or PPCL

Multiple Myeloma | Primary Plasma Cell Leukemia

China
Wuhan Union Hospital, China

Recruiting

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Multiple Myeloma | Extramedullary Multiple Myeloma | Primary Plasma Cell Leukemia

China
Aibin Liang，MD，Ph.D.
CARsgen Therapeutics Co., Ltd.

Recruiting

Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Relapsed and/or Refractory Multiple Myeloma | Plasma Cell Leukemia in Relapse

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Recruiting

Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

Plasma Cell Tumors

China
Hrain Biotechnology Co., Ltd.
Shanghai Changzheng Hospital

Recruiting

To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL

Multiple Myeloma | Plasma Cell Leukemia

China
Clinical Service, China
307 Hospital of PLA; Chinese PLA General Hospital; Peking University Third Hospital and other collaborators

Unknown

Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia (Bortezomib)

Multiple Myeloma | Plasma Cell Leukemia

China
The First Affiliated Hospital of Soochow University
CARsgen Therapeutics Co., Ltd.

Recruiting

CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Multiple Myeloma | Plasma Cell Leukemia

China
Nanjing IASO Biotechnology Co., Ltd.
Ruijin Hospital

Recruiting

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Plasma Cell Leukemia | Relapsed/Refractory Multiple Myeloma

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Neoplasm, Plasma Cell

China
Chongqing Precision Biotech Co., Ltd

Recruiting

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Neoplasm, Plasma Cell

China
Chunrui Li
Nanjing IASO Biotechnology Co., Ltd

Recruiting

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Plasma Cell Leukemia | Relapsed/Refractory Multiple Myeloma

China
Chongqing Precision Biotech Co., Ltd

Recruiting

a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Neoplasm, Plasma Cell

China
Institute of Hematology & Blood Diseases Hospital

Unknown

a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients

Multiple Myeloma | Plasma Cell Leukemia | Extramedullary Plasmacytoma | Loss of Chromosome 17p | t(14;16) | t(4;14) | Complex Karyotype | T(14;20) | 1Q21 Amplification

China
Peking Union Medical College Hospital

Recruiting

Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma

Solitary Plasmacytoma

China
Bing Han

Completed

Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA (PRCA)

Pure Red Cell Aplasia, Acquired

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Unknown

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Follicular Lymphoma | B Cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Plasma Cell Neoplasm | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Primary Cutaneous Follicle Centre Lymphoma

China
Nanjing Tongren Hospital

Unknown

CTC Detection Rate in SCCHN With a in Vivo Device

Squamous Cell Carcinoma of the Head and Neck | Circulating Tumor Cell

China
Nanjing University School of Medicine

Enrolling by invitation

Autologous Stem Cell Transplantation for Patients With AL Amyloidosis

AL Amyloidosis | Plasma Cell Dyscrasia

China
Xuzhou Central Hospital

Completed

Low-dose Protocol for Computed Tomography-guided Lung Biopsy

Lung Cancer, Adenocarcinoma | Lung Inflammatory Pseudotumor

China
Bing Han

Completed

Sirolimus Treatment for Refractory PRCA

Pure Red Cell Aplasia

China
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Plasma Cell Myeloma | RISS Stage I Plasma Cell Myeloma | RISS Stage II Plasma Cell Myeloma

United States
Peking Union Medical College Hospital

Unknown

Tacrolimus Treatment for Refractory PRCA

Pure Red Cell Aplasia

China
Sanofi

Completed

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients

Autologous Haematopoietic Stem Cell Transplant

China
Zhongnan Hospital

Unknown

Circulating Tumor Cell Capture for Early Diagnosis and Postoperative Tumor Recurrence Monitoring of Liver Cancer

Circulating Tumor Cell

China
Nanfang Hospital of Southern Medical University
Guangzhou First People's Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen... and other collaborators

Unknown

Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT

Multiple Myeloma | Conditioning | Autologous Hematopoietic Stem Cell Transplantation

China
Hebei Senlang Biotechnology Inc., Ltd.
Cangzhou People's Hospital

Recruiting

CAR-T Cells in the Treatment of Malignant Hematological Tumors

Lymphoma, B-Cell | Multiple Myeloma | Leukemia, T-Cell | Leukemia, B-cell

China
Peking Union Medical College Hospital

Recruiting

A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab

AL Amyloidosis

China
Chen Wenming
307 Hospital of PLA

Unknown

Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients

Multiple Myeloma in Relapse | Autologous Stem Cell Transplantation | Microtransplantation

China
Jin Lu, MD

Recruiting

Bortezomib, Pomalidomide, Dexamethasone For Systemic AL Amyloidosis

Systemic Amyloidosis

China
Institute of Hematology & Blood Diseases Hospital...

Terminated

Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment (BID-PERAL)

Acquired Pure Red Cell Aplasia

China
Jin Lu, MD

Recruiting

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

AL Amyloidosis | Amyloidosis; Systemic

China
Timmune Biotech Inc.
Hunan Provincial People's Hospital

Unknown

Treatment of Hematological Malignancy With Novel CAR-T Cells.

Multiple Myeloma | B-cell Acute Lymphoblastic Leukemia | B-cell Non Hodgkin Lymphoma

China
Peking Union Medical College Hospital

Unknown

Circulating Plasmablast in Diagnosis and Relapse Prediction of IgG4-RD

Plasmablast/Plasma Cells in Diagnosis of IgG4-RD | Plasmablast/Plasma Cells in Relapse Prediction of IgG4-RD

China
Sanofi

Active, not recruiting

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM (IRAKLIA)

Plasma Cell Myeloma Recurrent

Taiwan, Brazil, Greece, Japan, Turkey, Czechia, France, Norway, Chile, Spain, United Kingdom, Argentina, United States, Australia, Canada, China, Germany, Hungary, Italy, Poland, Sweden
Nanjing University School of Medicine

Completed

Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis

Amyloidosis

China
RenJi Hospital

Recruiting

CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial (CTCNeoBC-E)

Breast Cancer | Circulating Tumor Cell

China
Shanghai Changzheng Hospital
CARsgen Therapeutics Co., Ltd.

Recruiting

Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

China
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma

Multiple Myeloma

China
Bioray Laboratories
Second Xiangya Hospital of Central South University; Shanghai Tongji Hospital...

Suspended

Efficacy and Safety Evaluation of BCMA-UCART

Multiple Myeloma

China
Shanghai Tongji Hospital, Tongji University School...

Unknown

Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM

Multiple Myeloma

China
Shanghai General Hospital, Shanghai Jiao Tong University...

Unknown

Modified Bortezomib-based Combination Therapy for Multiple Myeloma

Multiple Myeloma

China
Chinese PLA General Hospital

Unknown

Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138 (CART-138)

Multiple Myeloma

China
Peking University

Available

Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy

Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital
Shanghai Kuaixu Biotechnology Co., Ltd

Recruiting

Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma

Multiple Myeloma

China
Shanghai Changzheng Hospital

Unknown

Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple Myeloma (EUCADD)

Multiple Myeloma

China
Peking University First Hospital

Recruiting

PET Imaging Study of 68Ga-NB381 in Multiple Myeloma

Multiple Myeloma

China
Shanghai Changzheng Hospital
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

Study of FasT CAR-T GC012F Injection NDMM Patients

Multiple Myeloma

China

Clinical Trials on Plasma Cell Neoplasm in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations